| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 28 | 2026 | 1491 | 3.320 |
Why?
|
| Stroke Volume | 16 | 2026 | 464 | 3.140 |
Why?
|
| Coronary Circulation | 5 | 2024 | 97 | 2.050 |
Why?
|
| Cardiac Catheterization | 12 | 2026 | 307 | 1.710 |
Why?
|
| Ventricular Function, Left | 10 | 2025 | 540 | 1.640 |
Why?
|
| Pulmonary Embolism | 4 | 2021 | 234 | 1.520 |
Why?
|
| Radial Artery | 5 | 2022 | 41 | 1.500 |
Why?
|
| Ventricular Dysfunction, Left | 9 | 2018 | 264 | 1.370 |
Why?
|
| Coronary Artery Disease | 9 | 2024 | 387 | 1.280 |
Why?
|
| Microcirculation | 4 | 2024 | 101 | 1.280 |
Why?
|
| Aortic Valve Stenosis | 5 | 2020 | 156 | 1.230 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2020 | 80 | 1.170 |
Why?
|
| Microvessels | 2 | 2019 | 70 | 1.110 |
Why?
|
| Vascular Calcification | 2 | 2019 | 48 | 1.090 |
Why?
|
| Coronary Vessels | 4 | 2024 | 178 | 1.020 |
Why?
|
| Thrombolytic Therapy | 3 | 2018 | 259 | 0.960 |
Why?
|
| Hemodynamics | 8 | 2026 | 747 | 0.890 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2019 | 81 | 0.870 |
Why?
|
| Benzazepines | 6 | 2012 | 64 | 0.860 |
Why?
|
| Ventricular Pressure | 4 | 2025 | 41 | 0.820 |
Why?
|
| Hospitalization | 7 | 2015 | 991 | 0.790 |
Why?
|
| Renal Insufficiency | 3 | 2015 | 101 | 0.760 |
Why?
|
| Ulnar Artery | 1 | 2022 | 8 | 0.710 |
Why?
|
| Echocardiography | 6 | 2026 | 783 | 0.710 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2019 | 66 | 0.710 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2021 | 14 | 0.660 |
Why?
|
| Heart Diseases | 2 | 2016 | 268 | 0.650 |
Why?
|
| Treatment Outcome | 24 | 2025 | 9711 | 0.640 |
Why?
|
| Coronary Artery Bypass | 3 | 2019 | 231 | 0.620 |
Why?
|
| Heart-Assist Devices | 5 | 2021 | 916 | 0.610 |
Why?
|
| Heart Arrest | 3 | 2018 | 321 | 0.600 |
Why?
|
| Humans | 75 | 2026 | 98080 | 0.600 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2019 | 107 | 0.590 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 17 | 0.590 |
Why?
|
| Electrocardiography | 2 | 2019 | 527 | 0.590 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 9 | 0.580 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 62 | 0.580 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 264 | 0.570 |
Why?
|
| Thrombosis | 2 | 2025 | 318 | 0.570 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 52 | 0.570 |
Why?
|
| Aged | 37 | 2026 | 21758 | 0.570 |
Why?
|
| Atherectomy, Coronary | 1 | 2018 | 2 | 0.560 |
Why?
|
| Coronary Angiography | 8 | 2023 | 237 | 0.560 |
Why?
|
| Cardiac Catheters | 1 | 2018 | 20 | 0.550 |
Why?
|
| Patient Readmission | 4 | 2017 | 425 | 0.540 |
Why?
|
| Retrospective Studies | 19 | 2026 | 10973 | 0.530 |
Why?
|
| Female | 50 | 2026 | 51536 | 0.530 |
Why?
|
| Male | 47 | 2026 | 47076 | 0.520 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 4 | 2012 | 27 | 0.520 |
Why?
|
| Device Removal | 1 | 2018 | 170 | 0.500 |
Why?
|
| Etiocholanolone | 4 | 2009 | 5 | 0.490 |
Why?
|
| Myocardium | 3 | 2018 | 578 | 0.490 |
Why?
|
| Cardio-Renal Syndrome | 2 | 2019 | 6 | 0.490 |
Why?
|
| Pericarditis, Constrictive | 1 | 2016 | 6 | 0.490 |
Why?
|
| Triage | 1 | 2018 | 151 | 0.490 |
Why?
|
| Middle Aged | 41 | 2026 | 29428 | 0.480 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 194 | 0.480 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 242 | 0.470 |
Why?
|
| Point-of-Care Systems | 4 | 2008 | 155 | 0.440 |
Why?
|
| Endoscopy | 1 | 2019 | 384 | 0.440 |
Why?
|
| Creatinine | 1 | 2015 | 313 | 0.430 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2681 | 0.430 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2025 | 339 | 0.430 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 7389 | 0.430 |
Why?
|
| Kidney | 2 | 2019 | 1123 | 0.430 |
Why?
|
| Shock, Cardiogenic | 3 | 2024 | 183 | 0.420 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 315 | 0.400 |
Why?
|
| Cardiotonic Agents | 3 | 2009 | 92 | 0.390 |
Why?
|
| Neurotransmitter Agents | 2 | 2019 | 102 | 0.380 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2666 | 0.380 |
Why?
|
| Ischemia | 3 | 2020 | 262 | 0.370 |
Why?
|
| Septal Occluder Device | 2 | 2025 | 52 | 0.370 |
Why?
|
| Risk Factors | 7 | 2021 | 6233 | 0.330 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 142 | 0.320 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 1782 | 0.310 |
Why?
|
| Popliteal Artery | 2 | 2020 | 32 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1173 | 0.310 |
Why?
|
| Absorbable Implants | 2 | 2020 | 38 | 0.310 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 91 | 0.300 |
Why?
|
| Pulmonary Wedge Pressure | 6 | 2026 | 123 | 0.300 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2019 | 238 | 0.290 |
Why?
|
| Vasopressins | 1 | 2008 | 49 | 0.280 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2019 | 266 | 0.280 |
Why?
|
| Vascular Resistance | 2 | 2019 | 98 | 0.280 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 110 | 0.280 |
Why?
|
| Prognosis | 9 | 2019 | 4116 | 0.270 |
Why?
|
| Weight Gain | 1 | 2009 | 134 | 0.270 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 194 | 0.270 |
Why?
|
| Amyloidosis | 1 | 2009 | 136 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 903 | 0.260 |
Why?
|
| Double-Blind Method | 7 | 2024 | 1782 | 0.250 |
Why?
|
| Angina Pectoris | 2 | 2023 | 18 | 0.250 |
Why?
|
| Biomarkers | 6 | 2019 | 2020 | 0.250 |
Why?
|
| Spironolactone | 2 | 2021 | 13 | 0.250 |
Why?
|
| Heart | 4 | 2019 | 527 | 0.240 |
Why?
|
| Cardiovascular Agents | 3 | 2012 | 62 | 0.230 |
Why?
|
| Time Factors | 7 | 2025 | 5567 | 0.230 |
Why?
|
| Hospital Mortality | 2 | 2021 | 541 | 0.230 |
Why?
|
| Foramen Ovale, Patent | 1 | 2025 | 23 | 0.230 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2025 | 61 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2025 | 194 | 0.220 |
Why?
|
| Splanchnic Nerves | 1 | 2024 | 8 | 0.220 |
Why?
|
| Causality | 2 | 2017 | 83 | 0.220 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2019 | 259 | 0.220 |
Why?
|
| Prospective Studies | 7 | 2019 | 4823 | 0.210 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 3 | 2009 | 89 | 0.210 |
Why?
|
| Myocardial Bridging | 1 | 2023 | 5 | 0.200 |
Why?
|
| Exercise Test | 1 | 2024 | 158 | 0.200 |
Why?
|
| Blood Pressure | 4 | 2008 | 910 | 0.190 |
Why?
|
| Vena Cava, Inferior | 4 | 2008 | 140 | 0.190 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 95 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2021 | 20 | 0.190 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 122 | 0.180 |
Why?
|
| Spasm | 1 | 2022 | 17 | 0.180 |
Why?
|
| Heart Atria | 3 | 2016 | 255 | 0.180 |
Why?
|
| Myocardial Revascularization | 2 | 2014 | 28 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 4025 | 0.170 |
Why?
|
| Comorbidity | 2 | 2017 | 1033 | 0.170 |
Why?
|
| Catheters | 1 | 2021 | 109 | 0.160 |
Why?
|
| Equipment Failure | 2 | 2018 | 119 | 0.160 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2784 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2021 | 108 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 473 | 0.160 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2020 | 4 | 0.160 |
Why?
|
| Equipment Design | 3 | 2018 | 425 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2020 | 2585 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 2013 | 0.150 |
Why?
|
| Mitral Valve | 2 | 2018 | 229 | 0.150 |
Why?
|
| Punctures | 1 | 2019 | 29 | 0.150 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2019 | 4 | 0.150 |
Why?
|
| Fibrosis | 2 | 2020 | 234 | 0.150 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 108 | 0.150 |
Why?
|
| Survival Rate | 3 | 2020 | 2041 | 0.150 |
Why?
|
| Sutureless Surgical Procedures | 1 | 2019 | 5 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 811 | 0.150 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2019 | 66 | 0.150 |
Why?
|
| Chronic Disease | 2 | 2019 | 985 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2009 | 62 | 0.140 |
Why?
|
| Illinois | 2 | 2018 | 522 | 0.140 |
Why?
|
| rho-Associated Kinases | 1 | 2020 | 162 | 0.140 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2018 | 14 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2019 | 296 | 0.140 |
Why?
|
| Hospitals | 1 | 2021 | 336 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2019 | 231 | 0.140 |
Why?
|
| Drug-Eluting Stents | 1 | 2018 | 24 | 0.140 |
Why?
|
| Atrial Function, Left | 1 | 2018 | 37 | 0.140 |
Why?
|
| Disease Progression | 2 | 2015 | 1610 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 39 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 219 | 0.140 |
Why?
|
| United States | 5 | 2019 | 8197 | 0.130 |
Why?
|
| Hospital Costs | 1 | 2019 | 117 | 0.130 |
Why?
|
| Hydroxyethylrutoside | 1 | 2017 | 2 | 0.130 |
Why?
|
| Myocardial Infarction | 3 | 2014 | 396 | 0.130 |
Why?
|
| Blood Circulation | 1 | 2017 | 29 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 321 | 0.130 |
Why?
|
| Heart Massage | 1 | 2017 | 11 | 0.130 |
Why?
|
| Allografts | 1 | 2018 | 220 | 0.130 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 110 | 0.130 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 192 | 0.130 |
Why?
|
| Renal Veins | 1 | 2017 | 28 | 0.120 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 32 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3606 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2016 | 16 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 179 | 0.120 |
Why?
|
| Health Status | 1 | 2018 | 385 | 0.120 |
Why?
|
| Ultrasonography | 5 | 2009 | 720 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 36 | 0.120 |
Why?
|
| Vena Cava Filters | 1 | 2017 | 92 | 0.120 |
Why?
|
| Catheterization | 1 | 2017 | 219 | 0.110 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 179 | 0.110 |
Why?
|
| Macrophages | 1 | 2019 | 643 | 0.110 |
Why?
|
| Upper Extremity | 1 | 2016 | 69 | 0.110 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2015 | 9 | 0.110 |
Why?
|
| Coronary Aneurysm | 1 | 2015 | 15 | 0.110 |
Why?
|
| Aortic Valve | 1 | 2017 | 258 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1567 | 0.110 |
Why?
|
| Hemostatic Techniques | 1 | 2014 | 17 | 0.110 |
Why?
|
| Incidence | 2 | 2017 | 1779 | 0.110 |
Why?
|
| Adult | 9 | 2025 | 29539 | 0.110 |
Why?
|
| Hemoptysis | 1 | 2014 | 26 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2019 | 664 | 0.110 |
Why?
|
| Contrast Media | 1 | 2019 | 1011 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1895 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 642 | 0.100 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2014 | 11 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 508 | 0.100 |
Why?
|
| Chicago | 2 | 2017 | 1513 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 92 | 0.100 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2015 | 101 | 0.100 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 1945 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2015 | 194 | 0.100 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 24 | 0.100 |
Why?
|
| Developed Countries | 1 | 2013 | 25 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1995 | 0.100 |
Why?
|
| Urbanization | 1 | 2013 | 20 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1284 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2019 | 1186 | 0.090 |
Why?
|
| Canada | 1 | 2013 | 211 | 0.090 |
Why?
|
| North America | 1 | 2013 | 210 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 802 | 0.090 |
Why?
|
| Software | 1 | 2017 | 693 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2015 | 381 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 246 | 0.090 |
Why?
|
| Dyspnea | 2 | 2010 | 90 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 939 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2013 | 227 | 0.090 |
Why?
|
| Hypotension | 1 | 2012 | 80 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2018 | 873 | 0.090 |
Why?
|
| Systole | 2 | 2008 | 81 | 0.080 |
Why?
|
| Adolescent | 3 | 2017 | 10080 | 0.080 |
Why?
|
| Heart Rate | 3 | 2008 | 534 | 0.080 |
Why?
|
| Recurrence | 2 | 2011 | 1254 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 299 | 0.080 |
Why?
|
| Vascular Patency | 2 | 2020 | 123 | 0.080 |
Why?
|
| Acute Disease | 5 | 2009 | 860 | 0.080 |
Why?
|
| Respiratory System Agents | 1 | 2009 | 7 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 60 | 0.070 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 30 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 1384 | 0.070 |
Why?
|
| Smoking | 1 | 2013 | 674 | 0.070 |
Why?
|
| Amyloid | 1 | 2009 | 104 | 0.070 |
Why?
|
| Cardiology | 1 | 2010 | 124 | 0.070 |
Why?
|
| Internationality | 1 | 2008 | 79 | 0.070 |
Why?
|
| Assisted Circulation | 1 | 2008 | 16 | 0.070 |
Why?
|
| Diastole | 3 | 2018 | 101 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1416 | 0.070 |
Why?
|
| Ventricular Function | 1 | 2008 | 41 | 0.070 |
Why?
|
| Prosthesis Design | 2 | 2019 | 308 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 119 | 0.070 |
Why?
|
| Atrial Function | 1 | 2007 | 16 | 0.070 |
Why?
|
| Remission Induction | 1 | 2009 | 754 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 37 | 0.060 |
Why?
|
| Hypertension | 1 | 2013 | 778 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 72 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1235 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 126 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2008 | 480 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 91 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 114 | 0.060 |
Why?
|
| ROC Curve | 1 | 2008 | 794 | 0.060 |
Why?
|
| Physical Examination | 1 | 2007 | 149 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2009 | 418 | 0.060 |
Why?
|
| Critical Care | 1 | 2010 | 483 | 0.060 |
Why?
|
| Obesity | 1 | 2013 | 1061 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2010 | 682 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 120 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2025 | 153 | 0.050 |
Why?
|
| Reference Values | 1 | 2025 | 608 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1950 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 462 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2006 | 357 | 0.050 |
Why?
|
| Program Development | 1 | 2023 | 141 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 193 | 0.050 |
Why?
|
| Sex Factors | 1 | 2025 | 1138 | 0.040 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.040 |
Why?
|
| Length of Stay | 2 | 2019 | 878 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 977 | 0.040 |
Why?
|
| Internship and Residency | 2 | 2007 | 1123 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 1962 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2020 | 43 | 0.040 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 29 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2024 | 399 | 0.040 |
Why?
|
| Algorithms | 3 | 2017 | 2002 | 0.040 |
Why?
|
| Frail Elderly | 1 | 2020 | 96 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 244 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 213 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 34 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2020 | 272 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 138 | 0.040 |
Why?
|
| Bioprosthesis | 1 | 2019 | 42 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 342 | 0.040 |
Why?
|
| American Heart Association | 1 | 2019 | 117 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 166 | 0.030 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 95 | 0.030 |
Why?
|
| Endocardium | 1 | 2018 | 81 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 484 | 0.030 |
Why?
|
| Prosthesis Fitting | 1 | 2017 | 17 | 0.030 |
Why?
|
| Phlebography | 1 | 2017 | 74 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 309 | 0.030 |
Why?
|
| Education, Medical | 1 | 2019 | 229 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 28894 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 523 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 59 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 275 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 640 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2014 | 11 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1094 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 71 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 137 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 161 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1224 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 503 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 55 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1122 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 1129 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 7507 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1527 | 0.020 |
Why?
|
| Furosemide | 1 | 2012 | 34 | 0.020 |
Why?
|
| Diuretics | 1 | 2012 | 79 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3328 | 0.020 |
Why?
|
| Sodium | 1 | 2012 | 330 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 674 | 0.020 |
Why?
|
| Edema, Cardiac | 1 | 2010 | 4 | 0.020 |
Why?
|
| Physical Exertion | 1 | 2010 | 39 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 764 | 0.020 |
Why?
|
| Dizziness | 1 | 2010 | 26 | 0.020 |
Why?
|
| Respiratory Sounds | 1 | 2010 | 40 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 99 | 0.020 |
Why?
|
| Pulmonary Atelectasis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 356 | 0.020 |
Why?
|
| Dobutamine | 1 | 2009 | 38 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 278 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 3620 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 438 | 0.020 |
Why?
|
| Heart, Artificial | 1 | 2008 | 9 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 412 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 59 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2007 | 38 | 0.020 |
Why?
|
| Positive-Pressure Respiration | 1 | 2007 | 55 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 76 | 0.020 |
Why?
|
| Jugular Veins | 1 | 2007 | 65 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2007 | 142 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 194 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 726 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 109 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 839 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 579 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 12698 | 0.010 |
Why?
|
| Organ Size | 1 | 2006 | 370 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1275 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 726 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 801 | 0.010 |
Why?
|